IN8bio to Present at Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference
IN8bio to Present at Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference
IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The company's lead program, INB-400, is in a Phase 2 trial in glioblastoma multiforme (GBM). Additional programs include Phase 1 trials in solid and hematologic tumors, including INB-200 for GBM and INB-100 for patients with hematologic malignancies undergoing transplantation. For more information about IN8bio, visit . NEW YORK, Dec. 02, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced that William Ho, CEO and co-founder, will present at NobleCon20 - Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference on Tuesday, December 3, 2024 at 10:30 am ET.
紐約，2024年12月2日（環球新聞通訊）-- in8bio公司（納斯達克代碼：INAB）是一家臨床階段的生物製藥公司，專注於開發創新的伽馬-德爾塔電芯療法，今天宣佈首席執行官兼聯合創始人William Ho將在2024年12月3日（星期二）上午10:30（東部時間）出席NobleCon20 - Noble資本市場第二十屆年度新興成長股權會議並進行演講。
A high-definition video webcast of the presentation will be available the following day on the Company's website and as part of a complete catalog of presentations available at Noble Capital Markets' Conference website: and on Channelchek the investor portal created by Noble. The webcast will be archived on the company's website, the NobleCon website, and on Channelchek.com for 90 days following the event.
演講的高清直播將在次日通過公司的官方網站提供，同時作爲Noble資本市場會議網站上的完整演講目錄的一部分，此外在Noble公司創建的投資者門戶Channelchek上也將可用。直播將在會議結束後90天內存檔於公司的官方網站、NobleCon網站和Channelchek.com上。
About IN8bio
關於in8bio
IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The company's lead program, INB-400, is in a Phase 2 trial in glioblastoma multiforme (GBM). Additional programs include Phase 1 trials in solid and hematologic tumors, including INB-200 for GBM and INB-100 for patients with hematologic malignancies undergoing transplantation. For more information about IN8bio, visit .
in8bio是一家臨床階段的生物製藥公司，開發針對癌症患者的伽馬-德爾塔電芯基礎免疫療法。伽馬-德爾塔電芯是一種特殊的電芯群體，具有獨特的特性，包括區分健康與疾病組織的能力。公司的主要項目INb-400正在進行膠質母細胞瘤（GBM）的二期臨床試驗。其他項目包括針對實質性和血液腫瘤的一級試驗，包括INb-200針對膠質母細胞瘤和INb-100針對接受移植的血液惡性腫瘤患者。有關in8bio的更多信息，請訪問。
Investors and Corporate Contacts:
Glenn Schulman, PharmD, MPH
203.494.7411
gdschulman@IN8bio.com
投資者和企業聯繫人：
格倫·舒爾曼，藥學博士，公共衛生碩士
203.494.7411
gdschulman@IN8bio.com
Patrick McCall, CFO
IN8bio, Inc
pfmccall@IN8bio.com
帕特里克·麥克考，首席財務官
IN8bio，Inc
pfmccall@IN8bio.com
Media Contact
Kimberly Ha
KKH Advisors
917.291.5744
kimberly.ha@kkhadvisors.com
媒體聯繫
Kimberly Ha
KKH Advisors
917.291.5744
kimberly.ha@kkhadvisors.com
